Cell-derived Microparticles in Atherosclerosis: Biomarkers and Targets for Pharmacological Modulation?

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2011 Nov 5

PMID 22050954

Citations 34

Authors

Morgane Baron

Chantal M Boulanger

Bart Staels

Anne Tailleux

Affiliations

Soon will be listed here.

Abstract

Cardiovascular diseases remain an important cause of morbi-mortality. Atherosclerosis, which predisposes to cardiovascular disorders such as myocardial infarction and stroke, develops silently over several decades. Identification of circulating biomarkers to evaluate cardiovascular event risk and pathology prognosis is of particular importance. Microparticles (MPs) are small vesicles released from cells upon apoptosis or activation. Microparticles are present in blood of healthy individuals. Studies showing a modification of their concentrations in patients with cardiovascular risk factors and after cardiovascular events identify MPs as potential biomarkers of disease. Moreover, the pathophysiological properties of MPs may contribute to atherosclerosis development. In addition, pharmacological compounds, used in the treatment of cardiovascular disease, can reduce plasma MP concentrations. Nevertheless, numerous issues remain to be solved before MP measurement can be applied as routine biological tests to improve cardiovascular risk prediction. In particular, prospective studies to identify the predictive values of MPs in pathologies such as cardiovascular diseases are needed to demonstrate whether MPs are useful biomarkers for the early detection of the disease and its progression.

Citing Articles

Associations between Erectile Dysfunction and Vascular Parameters: A Systematic Review and Meta-Analysis.

Peng H, Zhang H, Xin S, Li H, Liu X, Wang T World J Mens Health. 2024; 42(4):712-726.

PMID: 38311372 PMC: 11439810. DOI: 10.5534/wjmh.230192.

Extracellular Vesicles and Vascular Inflammation.

Yu P, Deng S, Yuan X, Pan J, Xu J Adv Exp Med Biol. 2023; 1418:105-117.

PMID: 37603275 DOI: 10.1007/978-981-99-1443-2_7.

Extracellular Vesicles in Coronary Artery Disease.

Buntsma N, van der Pol E, Nieuwland R, Gasecka A Adv Exp Med Biol. 2023; 1418:81-103.

PMID: 37603274 DOI: 10.1007/978-981-99-1443-2_6.

Exosomes and Their Bioengineering Strategies in the Cutaneous Wound Healing and Related Complications: Current Knowledge and Future Perspectives.

Yang G, Waheed S, Wang C, Shekh M, Li Z, Wu J Int J Biol Sci. 2023; 19(5):1430-1454.

PMID: 37056923 PMC: 10086759. DOI: 10.7150/ijbs.80430.

Different Contribution of Monocyte- and Platelet-Derived Microvesicles to Endothelial Behavior.

Brambilla M, Talmon M, Canzano P, Fresu L, Brunelleschi S, Tremoli E Int J Mol Sci. 2022; 23(9).

PMID: 35563201 PMC: 9105732. DOI: 10.3390/ijms23094811.

References

Leroyer A, Isobe H, Leseche G, Castier Y, Wassef M, Mallat Z . Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol. 2007; 49(7):772-7. DOI: 10.1016/j.jacc.2006.10.053. View

Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T . Losartan and simvastatin inhibit platelet activation in hypertensive patients. J Thromb Thrombolysis. 2005; 18(3):177-85. DOI: 10.1007/s11239-005-0343-8. View

Bernard S, Loffroy R, Serusclat A, Boussel L, Bonnefoy E, Thevenon C . Increased levels of endothelial microparticles CD144 (VE-Cadherin) positives in type 2 diabetic patients with coronary noncalcified plaques evaluated by multidetector computed tomography (MDCT). Atherosclerosis. 2008; 203(2):429-35. DOI: 10.1016/j.atherosclerosis.2008.07.039. View

Boulanger C, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A . Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation. 2001; 104(22):2649-52. DOI: 10.1161/hc4701.100516. View

Agouni A, Lagrue-Lak-Hal A, Ducluzeau P, Mostefai H, Draunet-Busson C, Leftheriotis G . Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol. 2008; 173(4):1210-9. PMC: 2543087. DOI: 10.2353/ajpath.2008.080228. View

ZWAAL R, Comfurius P, Bevers E . Mechanism and function of changes in membrane-phospholipid asymmetry in platelets and erythrocytes. Biochem Soc Trans. 1993; 21(2):248-53. DOI: 10.1042/bst0210248. View

Brodsky S, Zhang F, Nasjletti A, Goligorsky M . Endothelium-derived microparticles impair endothelial function in vitro. Am J Physiol Heart Circ Physiol. 2004; 286(5):H1910-5. DOI: 10.1152/ajpheart.01172.2003. View

Chironi G, Simon A, Hugel B, Del Pino M, Gariepy J, Freyssinet J . Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol. 2006; 26(12):2775-80. DOI: 10.1161/01.ATV.0000249639.36915.04. View

Kolowos W, Gaipl U, Sheriff A, Voll R, Heyder P, Kern P . Microparticles shed from different antigen-presenting cells display an individual pattern of surface molecules and a distinct potential of allogeneic T-cell activation. Scand J Immunol. 2005; 61(3):226-33. DOI: 10.1111/j.1365-3083.2005.01551.x. View

10.

Leroyer A, Ebrahimian T, Cochain C, Recalde A, Blanc-Brude O, Mees B . Microparticles from ischemic muscle promotes postnatal vasculogenesis. Circulation. 2009; 119(21):2808-17. DOI: 10.1161/CIRCULATIONAHA.108.816710. View

11.

Lacroix R, Robert S, Poncelet P, Dignat-George F . Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost. 2010; 36(8):807-18. DOI: 10.1055/s-0030-1267034. View

12.

Pirro M, Schillaci G, Bagaglia F, Menecali C, Paltriccia R, Mannarino M . Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. Atherosclerosis. 2007; 197(2):757-67. DOI: 10.1016/j.atherosclerosis.2007.07.012. View

13.

Bernal-Mizrachi L, Jy W, Jimenez J, Pastor J, Mauro L, Horstman L . High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J. 2003; 145(6):962-70. DOI: 10.1016/S0002-8703(03)00103-0. View

14.

Kagawa H, Nomura S, Nagahama M, Ozaki Y, Fukuhara S . Effect of bezafibrate on soluble adhesion molecules and platelet activation markers in patients with connective tissue diseases and secondary hyperlipidemia. Clin Appl Thromb Hemost. 2001; 7(2):153-7. DOI: 10.1177/107602960100700213. View

15.

Connor J, Pak C, ZWAAL R, Schroit A . Bidirectional transbilayer movement of phospholipid analogs in human red blood cells. Evidence for an ATP-dependent and protein-mediated process. J Biol Chem. 1992; 267(27):19412-7. View

16.

Barry O, Pratico D, Lawson J, FitzGerald G . Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest. 1997; 99(9):2118-27. PMC: 508042. DOI: 10.1172/JCI119385. View

17.

Fievet C, Staels B . Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease. Curr Atheroscler Rep. 2009; 11(4):281-8. DOI: 10.1007/s11883-009-0043-5. View

18.

Nomura S, Kanazawa S, Fukuhara S . Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens. 2002; 16(8):539-47. DOI: 10.1038/sj.jhh.1001447. View

19.

Yuan A, Farber E, Rapoport A, Tejada D, Deniskin R, Akhmedov N . Transfer of microRNAs by embryonic stem cell microvesicles. PLoS One. 2009; 4(3):e4722. PMC: 2648987. DOI: 10.1371/journal.pone.0004722. View

20.

Sebbagh M, Renvoize C, Hamelin J, Riche N, Bertoglio J, Breard J . Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol. 2001; 3(4):346-52. DOI: 10.1038/35070019. View